Aidport Sp. z o.o. — Clinical Trial Site

72 Registered trials

39 Currently recruiting

Organisation

Aidport Sp. z o.o.

Location

Skorzewo, Poland

Identifier

ORG-100049010

Address

Ul Ksiedza Stanisława Kozierowskiego 24, 60-185, Poland

Departments

-
#2303 : Onkologia Kliniczna
#9004: oncology
2803 : NA
4102
AIDPORT
Aidport Sp z o o
Aidport sp z o.o.
AIDPORT Sp. z o.o.
AIDPORT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Gynaecology
Hematology
N/A
NA
Oncology
PL30003: Hematooncology
Poradnia Onkologiczna

Clinical trials at this site (72)

Search interface

An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting

2024-520156-22-00 Metastatic hormone-sensitive prostate cancer 4 2025-10-08
A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting

2024-519152-82-00 Relapsed/Refractory Follicular Lymphoma 5 2025-09-03
Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting

2024-518154-16-00 non-small cell lung cancer 5 2025-08-27
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with Immune Thrombocytopenia Recruiting

2024-520359-26-00 Immune Thrombocytopenia (ITP) 4 2025-08-20
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) i… Recruiting

2024-516633-12-00 Locally advanced/ metastatic gastroesophageal junction 5 2025-06-30
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient… Recruiting

2023-510026-32-00 Generalized Myasthenia Gravis 5 2025-06-11
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi… Recruiting

2024-515593-27-00 relapsed or refractory mantle cell lymphoma (R/R MCL) 5 2025-05-08
Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting

2023-509632-26-00 Recurrent or Metastatic Solid Tumors (endometrial cance 9 2025-02-11
An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring Recruiting

2024-515457-21-00 Non-Hodgkin lymphoma and chronic lymphocytic leukemia 3 2024-12-30
Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting

2024-513098-31-00 Relapsed or Refractory Aggressive B-cell Non-Hodgkin Ly 4 2024-11-14
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN) Recruiting

2024-511688-27-00 Myelofibrosis 4 2024-09-19
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 moderate thrombocytopenia 4 2024-07-17
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting

2023-510541-25-00 Relapsed/Refractory B-cell Malignancies 1 2023-10-09
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemi… Recruiting

2023-507396-21-00 transfusion-dependent α- or β-thalassemia or low-risk m 4 2023-03-16
A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting

2023-507699-38-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2022-08-30
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim… Recruiting

2024-510690-16-00 Relapsed/refractory follicular lymphoma 5 2022-01-31
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C… Recruiting

2024-515273-10-00 Relapsed or refractory Multiple Myeloma (r/r MM) 7 2021-10-19
A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 Ended

2023-509338-21-00 Primary immune thrombocytopenia 4 2025-05-28
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16